Value-Based Pricing
Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data. A new OHE…
OHE at ISPOR Europe: Posters
13 November 2014
The OHE presented the following posters at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.
OHE at ISPOR Europe 1: Impact of NICE on Innovation and Value
22 October 2014
ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions.…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics.
Pricing Variations Within and Across Countries: Gauging Efficiency
25 February 2014
This research explores which approaches to pricing can produce the greatest efficiency and access to medicines within and across countries. OHE collaborated on two articles published…
OHE at HESG: Value-based Assessment in the UK; Developing the EQ-5D-5L
23 January 2014
OHE’s contributions focused on approaches to implementing UK value-based assessment and the details of creating an EQ-5D-5L value set for England. The Health Economists’ Study Group…
Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison,…
Performance-Based Risk Sharing in Health Care: Current Status
17 April 2013
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on…
The Economics of the Market for Medicines: 2013 Review
26 March 2013
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2013 activities, he recently gave…